PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
January 26, 2026Molecular Cancer Therapeutics1 citations

DSP502 Dual Inhibition of PD-L1 and PVR Enhances Anti-Cancer Immune Responses

DSP502 combines dual inhibition of PD-L1 and PVR to trigger anti-cancer immune responses

View Full Paper
Ask AI
Bookmark
Share

Authors

VGVinicio A. Melo GallegosSGShirley GreenwaldATAmi Tamir

Discussion

Loading...

Member takes

Overview

Combination therapy using DSP502 shows improved anti-cancer immune responses in NSCLC and colorectal cancer, suggesting new treatment avenues.

Key Points

  • This research aimed to explore the dual inhibition of PD-L1 and PVR using DSP502 to improve cancer immune responses.
  • Developed DSP502 composed of extracellular domains of TIGIT and PD-1 fused to human IgG1 Fc.
  • Evaluated the effects of DSP502 on NK cell activation and anticancer cytotoxicity in PBMCs and TILs.
  • Conducted transcriptomic analysis to assess co-expression of TIGIT and PD-1 in NSCLC.
  • Tested DSP502 in xenograft models of ovarian and lung cancer.
  • DSP502 enhanced NK cell activation and cytotoxicity against cancer cells expressing PD-L1 and PVR.
  • Treatment preserved DNAM-1 expression on T and NK cells, promoting further immunity.
  • In xenograft studies, DSP502 significantly inhibited tumor growth.

Cite This Study

Gallegos et al. (2026) studied this question.

synapsesocial.com/papers/6977032e722626c4468e83dfhttps://doi.org/10.1158/1535-7163.mct-25-0102
View Full Paper
Ask AI
Bookmark
Share